ATLANTA , March 24, 2021 /PRNewswire/ — NeuroTrauma Sciences, LLC (NTS), a personal biopharmaceutical firm creating a portfolio of disease-modifying therapeutic candidates to deal with the devastating results of acquired mind damage, at the moment introduced the growth of its govt administration staff with a number of key appointments: Judith Hedstrom has been appointed Chief Working Officer, Anthony Caggiano , M.D., Ph.D., has been appointed Chief Medical Officer and Head of Analysis & Growth, and David Lawrence has been appointed Chief Monetary Officer.
Ms. Hedstrom joined NeuroTrauma Sciences as Vice President of Operations shortly after its founding and is assuming the position of Chief Working Officer, chargeable for the strategic and operational management of the corporate. She is an completed govt chief, with greater than 25 years’ expertise in accelerating life science product growth and development. She has held quite a few govt roles, together with Senior Vice President of Company and Enterprise Growth and Chief Working Officer of Alteon Inc., a publicly held biopharmaceutical firm, and Vice President of Strategic Planning and Enterprise Growth for APACHE Medical Programs, additionally a public firm. As well as, Judy has consulted to biotechnology, pharmaceutical, medical merchandise and diagnostic firms on a wide range of high-impact issues, and has assumed transitional govt management positions at a number of life science firms.
Dr. Caggiano brings greater than 20 years of management within the biopharmaceutical trade to the NTS administration staff in his position as Chief Medical Officer and Head of Analysis & Growth. He’s a broad-based therapeutic growth govt with expertise throughout a number of therapeutic modalities and indications, with a give attention to neurological issues. He has served within the position of Chief Medical Officer for Cognition Therapeutics, Fixed Prescribed drugs and Aeromics, Inc., clinical-stage firms creating candidates for central nervous system issues, together with stroke and in addition served as senior vp of analysis and growth at Acorda Therapeutics, a fully-integrated biopharmaceutical firm creating and commercializing novel therapies that enhance perform throughout a number of neurological issues.
Mr. Lawrence brings important monetary experience and biotechnology-focused management to NeuroTrauma Sciences in his new place as Chief Monetary Officer and he’ll assume accountability for the oversight of NTS’s monetary operations. His greater than 20 years at Acorda Therapeutics spanned a number of monetary roles together with Chief, Enterprise Operations and Principal Accounting Officer and Chief Monetary Officer. At Acorda, Mr. Lawrence managed and efficiently accomplished the corporate’s IPO, managed a number of follow-on choices and personal placements, elevating a complete of greater than $700 million .
“Judy’s expanded position and the addition of Tony and Dave to NTS’s govt staff are well timed as we put together to advance our lead program NTS-104 to an IND submission later this yr,” mentioned Carl Lengthy , Chief Govt Officer. “Their wealth of experiences throughout the trade might be invaluable as we construct an built-in biopharmaceutical firm centered on therapies for acquired mind accidents.”
About NeuroTrauma Sciences
NeuroTrauma Sciences (NTS) is a biopharmaceutical firm advancing its mission to develop therapies that deal with the total complexities of acquired mind accidents together with ischemic stroke, traumatic mind damage (TBI), and different neurologic situations. Acquired mind accidents stay areas of excessive unmet want with restricted therapeutic choices to alleviate the cognitive, practical, and neurobehavioral results for the hundreds of thousands of sufferers, worldwide. By following the science and leveraging insights into the biology of acquired mind damage, NTS is advancing a pipeline of candidates focusing on ischemic stroke and TBI. For extra data, please go to www.neurotraumasciences.com .
Vice President of Company Growth
View authentic content material: http://www.prnewswire.com/news-releases/neurotrauma-sciences-announces-expansion-of-its-executive-leadership-team-301255129.html
SOURCE Neurotrauma Sciences LLC